| pubmed-article:9044880 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9044880 | lifeskim:mentions | umls-concept:C0162429 | lld:lifeskim |
| pubmed-article:9044880 | lifeskim:mentions | umls-concept:C0030567 | lld:lifeskim |
| pubmed-article:9044880 | lifeskim:mentions | umls-concept:C0282151 | lld:lifeskim |
| pubmed-article:9044880 | lifeskim:mentions | umls-concept:C0011155 | lld:lifeskim |
| pubmed-article:9044880 | lifeskim:mentions | umls-concept:C0814225 | lld:lifeskim |
| pubmed-article:9044880 | lifeskim:mentions | umls-concept:C0255374 | lld:lifeskim |
| pubmed-article:9044880 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9044880 | pubmed:dateCreated | 1997-3-5 | lld:pubmed |
| pubmed-article:9044880 | pubmed:abstractText | Loss of striatal dopamine (DA) transporters in Parkinson's disease (PD) has been accurately assessed in vivo by single-photon emission tomography (SPET) studies using [123I]beta-CIT. However, these studies have also shown that adequate imaging of the striatal DA transporter content can be performed only 20-30 h following the injection of [123I]beta-CIT, which is not convenient for routine out-patient evaluations. Recently, a new ligand, N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) tropane (FP-CIT), became available for in vivo imaging of the DA transporter. The faster kinetics of [123I]FP-CIT have been shown to allow adequate acquisition as early as 3 h following injection. In the present study, loss of striatal DA transporters in five non-medicated PD patients was assessed on two consecutive SPET scans, one with [123I]beta-CIT (24 h following injection) and one with [123I]FP-CIT (3 h following injection). The ratios of specific to non-specific [123I]FP-CIT uptake in the caudate nucleus and putamen were consistently 2.5-fold lower than those of [123I]beta-CIT. However, when the uptake ratio of both ligands in these brain regions of patients was expressed as a percentage of the uptake ratio found in healthy controls, both the decrease and the variation of the data were similar. It is concluded on the basis of these findings that [123I]FP-CIT seems as good as [123I]beta-CIT for the assessment of the dopaminergic deficit in PD. The faster kinetics of [123I]FP-CIT are a clear advantage. | lld:pubmed |
| pubmed-article:9044880 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9044880 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9044880 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9044880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9044880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9044880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9044880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9044880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9044880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9044880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9044880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9044880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9044880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9044880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9044880 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9044880 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:9044880 | pubmed:issn | 0340-6997 | lld:pubmed |
| pubmed-article:9044880 | pubmed:author | pubmed-author:StoofJ CJC | lld:pubmed |
| pubmed-article:9044880 | pubmed:author | pubmed-author:BoerG JGJ | lld:pubmed |
| pubmed-article:9044880 | pubmed:author | pubmed-author:WoltersE CEC | lld:pubmed |
| pubmed-article:9044880 | pubmed:author | pubmed-author:van RoyenE... | lld:pubmed |
| pubmed-article:9044880 | pubmed:author | pubmed-author:BooijJJ | lld:pubmed |
| pubmed-article:9044880 | pubmed:author | pubmed-author:WinogrodzkaAA | lld:pubmed |
| pubmed-article:9044880 | pubmed:author | pubmed-author:TissinghGG | lld:pubmed |
| pubmed-article:9044880 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9044880 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:9044880 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9044880 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9044880 | pubmed:pagination | 68-71 | lld:pubmed |
| pubmed-article:9044880 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:meshHeading | pubmed-meshheading:9044880-... | lld:pubmed |
| pubmed-article:9044880 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9044880 | pubmed:articleTitle | Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. | lld:pubmed |
| pubmed-article:9044880 | pubmed:affiliation | Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, The Netherlands. | lld:pubmed |
| pubmed-article:9044880 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9044880 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:9044880 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9044880 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9044880 | lld:pubmed |
